C-F5KGFauna Bio
AI drug discovery, comparative genomics, natural disease resistance
discoverydiscoveringsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-F5KG
C-F5KGC-F5KGAI drug discovery, comparative genomics, natural disease resistance
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Fauna Bio AI drug discovery, comparative genomics, natural disease resistance
Fauna Bio is an AI-driven drug discovery company using genetic data from extreme mammalian models to identify therapeutic targets. Its Convergence platform is used to study natural disease resistance, including metabolic shifts, obesity resistance, muscle preservation, regeneration, and radiation protection. The company has a multi-year obesity discovery collaboration with Eli Lilly and space-focused programs funded by NASA-related initiatives and other space agencies.
The published score reflects a curated read of public evidence across 16 dimensions. Each dimension below shows the rationale we used. Disagree with a reading? Tell us where we are wrong →
Higher up = higher Eternal Search score. Further right = closer to achieving real longevity outcomes (early mechanism → translational → near-term readout). Bubble size = capital deployed. Watch for MISMATCHES: big bubbles on the left are well-capitalized but far from goals; small bubbles on the right are doing more with less.
Fauna Bio — Early mechanism · Bottom quartile. Derived deterministically from 16 extracted project(s). Most-advanced status: preclinical. Band: early_mechanism. Modifiers: +5 depth (3 programs at preclinical).…
Source: Deterministic